Journal of Pharmacovigilance

Breast cancer and cancer drug safety

4^th International Conference and Exhibition on Pharmacovigilance & Clinical Trials

August 10-12, 2015 London, UK

Ashok Srivastava, Ramesh Anumolu and Pallavi Dhillon

Posters-Accepted Abstracts: J Pharmacovigilance

Abstract:

Breast cancer remained the most common cancer in women and its incidence continues to rise. Nonetheless, mortality is falling, partly as a result of earlier diagnosis through mammographic screening, improved surgical techniques and attention to margins, improved delivery of radiotherapy, and better adjuvant medical therapies. Despite these improvements, breast cancer remains the second most common cause of death from cancer in women. About one-third of newly diagnosed patients will eventually recur and/ or develop metastatic disease. One of the old cancer drugs, doxorubicin is one of the most active and versatile anticancer agents. It has an exceptionally broad spectrum of activity, and plays a leading role in the curative and palliative therapy of a diverse group of malignancies, most notably breast cancer, lymphoma, soft tissue sarcoma, various pediatric malignancies, multiple myeloma, and advanced bladder cancer. But its use is limited by cardiotoxicity. The incidence of clinically significant cardiomyopathy or congestive heart failure rises with increasing lifetime cumulative doses of doxorubicin and also the other drug given in a combination regimen that includes drugs such as cyclophosphamide or paclitaxel, as well as newer biologic therapies, including trastuzumab. The breast cancer drug?s safety and pharmacovigilance will be discussed and presented at this meeting in detail along with breast cancer patient?s care.